Harrow Inc
Harrow Inc (HROW) Covered Calls
Harrow Inc trades in the Drug Manufacturers - Specialty & Generic industry with an IV Rank of 98.41%, high versus the past year. HROW's highest covered call setup is the $36.00 strike expiring Nov 20, 2026, sorted by theoretical annualized return. It's 38.25% out of the money with 15 days to expiration, a 38.44% return until expiration, and a 935.39% theoretical annualized return. Across the setups shown, annualized returns run from 125.56% to 935.39% at strikes between $27.00 and $55.00, with 15 to 316 days to expiration, as of Nov 5, 2026.
Read more
Running HROW covered calls helps you generate income from Harrow Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best HROW covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If HROW stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling HROW covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given HROW covered call is worth writing.
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.
| 2026-11-20 | 15 | 36.00 | 38.25 | 0.05 | 3.50 | 1001.00 | 38.44 | 935.39 | -0.19 | +0.30 | 3 | 3.45 |
| 2026-11-20 | 15 | 35.00 | 34.41 | 0.10 | 1.05 | 906.00 | 34.79 | 846.62 | -0.38 | +0.17 | 266 | 0.95 |
| 2027-01-15 | 71 | 45.00 | 72.81 | 0.20 | 2.00 | 1916.00 | 73.58 | 378.26 | -0.77 | +0.19 | 2,250 | 1.80 |
| 2026-11-20 | 15 | 29.00 | 11.37 | 0.40 | 4.00 | 336.00 | 12.90 | 313.98 | -1.54 | +0.43 | 0 | 3.60 |
| 2027-01-15 | 71 | 40.00 | 53.61 | 0.05 | 1.50 | 1401.00 | 53.80 | 276.59 | -0.19 | +0.17 | 4,760 | 1.45 |
| 2026-11-20 | 15 | 28.00 | 7.53 | 0.65 | 4.20 | 261.00 | 10.02 | 243.89 | -2.50 | +0.47 | 1 | 3.55 |
| 2026-11-20 | 15 | 27.00 | 3.69 | 1.50 | 4.40 | 246.00 | 9.45 | 229.88 | -5.76 | +0.52 | 0 | 2.90 |
| 2027-01-15 | 71 | 35.00 | 34.41 | 0.55 | 3.30 | 951.00 | 36.52 | 187.75 | -2.11 | +0.33 | 1,280 | 2.75 |
| 2027-09-17 | 316 | 55.00 | 111.21 | 0.35 | 4.70 | 2931.00 | 112.56 | 130.01 | -1.34 | +0.29 | 18 | 4.35 |
| 2027-01-15 | 71 | 32.00 | 22.89 | 0.40 | 4.20 | 636.00 | 24.42 | 125.56 | -1.54 | +0.39 | 20 | 3.80 |
As of Nov 5, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →Stock Statistics
- IndustryDrug Manufacturers - Specialty & Generic
- SectorHealthcare
- IV Rank98.41% High
- Market cap (M$)976
- 52 weeks high-52.53%
- 52 weeks low-3.41%
- Analyst recommendationStrong Buy
1.00 - Target price$63.78
139.85% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-09
- P/E—
- Future P/E12.36
- EPS (ttm)-1.00
- EPS growth next 5 years—
As of Nov 5, 2026